Speakers
Alan Aberdeen
Sola Adeleke
Pierre Arsène
Debora Lucarelli
Innovation showcase
Come and hear from 5 of the most exciting organisations working in this space as they walk us through their achievements, and how they will change the landscape. Vote for the one you think will have the greatest impact to give them a chance to speak again in the final plenary session
Sola founded Curenetics, a cancer AI deep-tech company developing models to predict responses to cancer immunotherapy treatments. They also lead in developing next-generation AI-driven cancer vaccines. Sola, an oncologist, completed a PhD at University College London, where he developed imaging-derived biomarkers for predicting cancer responses.
Pierre is an experienced biotech entrepreneur and former investment banker with multidisciplinary expertise spanning the full product lifecycle of innovative life sciences technologies. His expertise encompasses roles as a founder, inventor, operator, and advisor, guiding innovations from concept through development to market, securing financing, and contributing to successful exits.
While conducting postgraduate research in biophysics, nanoelectronics, and extracellular vesicles (EVs) at the University of Cambridge, he founded Mursla Bio, pioneering a novel model for spinning out university research while retaining intellectual property. He is the author and inventor of several patents and publications in nanoelectronics and EV characterisation and has received multiple innovation awards, including recognition as a German-French Young Leader under President Macron’s patronage.
Previously, Pierre spent a decade in healthcare investment banking at J.P. Morgan, closing over $70 billion in transactions and becoming the first representative sent to Japan to support global M&A initiatives. His contributions earned him recognition by eFinancialCareers as one of the most impressive Vice Presidents in investment banking.
He holds a Master in Management from HEC Paris and a classe préparatoire specializing in mathematics from Saint-Jean de Douai (equivalent to the undergraduate level).
Debora is an innovator and leader in the field of genomic technologies with medical applications. She joined Tagomics in the role of CTO at the beginning of 2024. Her expertise in the development and commercialisation of genomics-based platform technologies was most recently demonstrated in her role as CEO of Enhanc3D Genomics, where she led the company through three successful funding rounds, technology development and platform commercialisation. In previous roles Debora led biomarker discovery as Director Biomarker Discovery at Biomodal (formerly Cambridge Epigenetix), directed and managed laboratory operations and large population studies as the Head of Laboratory at the MRC Epidemiology (University of Cambridge) and managed a team to advance Oxford Nanopore’s technology
Dr Emilia Molimpakis is the CEO & Co-founder of thymia, building world-first biomarker-powered Voice AI Agents that measure health from 15 seconds of speech.
Our clinical-grade, regulated biomarkers detect mental health conditions, wellness indicators, and physical health issues with >90% accuracy - now deployed through our own health & safety voice agents across healthcare, automotive, and defence sectors globally. Previously spent 12 years researching language as a biomarker for cognitive health, mostly at UCL (PhD & post-docs in Neuroscience and Linguistics). Thought leader in mental health and voice AI, recently named one of TIME's World's Top HealthTech Companies.